The role of DNA repair in chronic lymphocytic leukemia pathogenesis and chemotherapy resistance
- PMID: 17706164
- DOI: 10.1007/s11912-007-0048-6
The role of DNA repair in chronic lymphocytic leukemia pathogenesis and chemotherapy resistance
Abstract
Front-line therapy for chronic lymphocytic leukemia (CLL) with alkylating agents is associated with low rates of complete remission and no improvement in overall survival. The ability of CLL cells to efficiently repair alkylator-induced damage to DNA might explain this lack of response. Novel strategies that inhibit DNA repair, such as combinations of alkylating agents, purine nucleoside analogues, and immunotherapy, have produced durable clinical and molecular remission in both untreated and relapsed CLL. This review evaluates the contribution of DNA repair processes in the development of resistance to chemotherapy and the impact of therapies that exploit the DNA repair capacity of CLL cells to therapeutic advantage.
Similar articles
-
Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.Semin Oncol. 2000 Apr;27(2 Suppl 5):44-51. Semin Oncol. 2000. PMID: 10877052 Review.
-
DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine.Clin Cancer Res. 2001 Nov;7(11):3580-9. Clin Cancer Res. 2001. PMID: 11705880
-
DNA repair and cellular resistance to alkylating agents in chronic lymphocytic leukemia.Clin Cancer Res. 1997 Nov;3(11):2055-61. Clin Cancer Res. 1997. PMID: 9815597
-
Complex chromosomal aberrations in chronic lymphocytic leukemia are associated with cellular drug and irradiation resistance.Eur J Haematol. 2000 Jul;65(1):32-9. doi: 10.1034/j.1600-0609.2000.9c153.x. Eur J Haematol. 2000. PMID: 10914937
-
Advances in chemotherapy for chronic lymphocytic leukemia.Semin Hematol. 2004 Jul;41(3):224-33. doi: 10.1053/j.seminhematol.2004.05.004. Semin Hematol. 2004. PMID: 15269882 Review.
Cited by
-
Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro.Leuk Res. 2014 Mar;38(3):411-7. doi: 10.1016/j.leukres.2013.12.019. Epub 2013 Dec 30. Leuk Res. 2014. PMID: 24439051 Free PMC article.
-
ZRF4, a combi-molecule with increased efficacy as compared with the individual components in chronic lymphocytic leukemia lymphocytes in vitro.Leukemia. 2011 Sep;25(9):1512-6. doi: 10.1038/leu.2011.110. Epub 2011 Jun 7. Leukemia. 2011. PMID: 21647162 Free PMC article. No abstract available.
-
Telomerase contributes to fludarabine resistance in primary human leukemic lymphocytes.PLoS One. 2013 Jul 29;8(7):e70428. doi: 10.1371/journal.pone.0070428. Print 2013. PLoS One. 2013. PMID: 23922990 Free PMC article.
-
Targeting and processing of site-specific DNA interstrand crosslinks.Environ Mol Mutagen. 2010 Jul;51(6):527-39. doi: 10.1002/em.20557. Environ Mol Mutagen. 2010. PMID: 20196133 Free PMC article. Review.
-
Involvement of classic and alternative non-homologous end joining pathways in hematologic malignancies: targeting strategies for treatment.Exp Hematol Oncol. 2021 Nov 3;10(1):51. doi: 10.1186/s40164-021-00242-1. Exp Hematol Oncol. 2021. PMID: 34732266 Free PMC article. Review.